

Biotechnology/Chemical/Pharmaceutical Customer Partnership

Monday, September 24, 2018

United States Patent and Trademark Office
USPTO Main Campus (**Alexandria**), Madison Auditorium

10:00 – 10:10am (EDT)	Welcoming and Opening Remarks	Gary Jones Director, TC1600, USPTO Daniel Sullivan Director, TC1600, USPTO Andrew Wang Director, TC1600, USPTO
10:10 – 11:00am (EDT)	Obviousness of Biologics: Identifying the Biggest Challenges	Carla Mouta-Bellum, Partner, Arrigo, Lee, Guttman & Mouta-Bellum LLP
11:00 – 11:50am (EDT)	Exemplary Obviousness Rationales Suggested in KSR	Lora Driscoll QAS, TC1600, USPTO
11:50am – 12:50pm (EDT)	BREAK/LUNCH	
12:50 – 1:40pm (EDT)	112(f)-New Form Paragraphs	Marjorie Moran, QAS TC1600, USPTO
1:40 – 2:40pm (EDT)	Requirements for Information Under 37 CFR 1.105 and Responses to Said Requirements	Amjad Abraham, SPE Shubo (Joe) Zhou, SPE TC1600, USPTO
2:40 – 3:00pm (EDT)	BREAK	
3:00 – 3:50pm (EDT)	Accidental Infringement: the need for additional limitations in plant utility claims directed to chemical profiles or cultivars	Reggie Gaudino, Chief Science Officer, Steep Hill Labs, Inc.
3:50 – 4:00pm (EDT)	Closing Remarks	Directors, TC1600, USPTO